Targeting Hepatitis B Virus With CRISPR/Cas9

doi:10.1038/mtna.2014.68

PMC full text:

Mol Ther Nucleic Acids. 2014 Dec; 3(12): e216.

Published online 2014 Dec 16. doi: 10.1038/mtna.2014.68

Copyright/LicenseRequest permission to reuse: Copyright © 2014 American Society of Gene & Cell Therapy
This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

<< PrevFigure 1Next >>

Figure 1

An external file that holds a picture, illustration, etc.
Object name is mtna201468f1.jpg

Open in a separate window

Life cycle and genomic organization of HBV. (a) The enveloped infectious HBV particle is uncoated after infection releasing the capsid (1) that migrates to the cell nucleus where it delivers the genomic rcDNA (2) which is converted into cccDNA (3), the template for transcription of the viral RNAs. (b) Physical map of HBV with the four open-reading frames and viral RNAs. Also indicated are the positions of enhancers I and II (EN1, EN2). For additional details, see ref. 5.

Figure 1

Images in this article

Click on the image to see a larger version.